Edoxaban Population Pharmacokinetics in Chinese Patients with Nonvalvular Atrial Fibrillation: Model-Informed Dose Adjustment
Thrombosis and Haemostasis · 12.02.2026
DOI: 10.1055/a-2802-3641 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 12.02.2026. Verfasst von Yuanrui Deng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Key Laboratory of Pulmonary Vascular Medicine, State Key Laboratory of Cardiovascular Disease, Center for Respiratory and P…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National High-Level Hospital Clinical Research Funding, Fuwai Hospital Chinese Academy of Medical Sciences.
Abstract (Originalsprache)
Edoxaban is a novel oral anticoagulant that directly inhibits factor Xa. The ENGAGE population pharmacokinetic (PopPK) model was established using data from the ENGAGE AF-TIMI 48 trial, which included over 21,000 participants, predominantly (81%) White/Caucasian individuals. However, its applicability to Chinese patients necessitates further evaluation. This study assessed the suitability of the ENGAGE PopPK model for Chinese patients with nonvalvular atrial fibrillation (NVAF). We analyzed 730 pharmacokinetic (PK) plasma samples from 104 Chinese NVAF patients using nonlinear mixed-effects modeling. A two-compartment model with first-order absorption and linear elimination optimally described the PK data of edoxaban in this cohort. Body weight (WT) and creatinine clearance were identified as significant covariates of apparent clearance (CL/F), and positively correlated with CL/F. Model-based simulations demonstrated that, in the 30 mg once-daily (q.d.) dosing group, patients with moderate renal impairment and low WT experienced higher systemic exposure than those with only one of these attributes. Additionally, patients with moderate renal impairment, whether alone or combined with low WT, displayed elevated steady-state trough concentrations (Cmin,ss) compared to those receiving the 60 mg q.d. dose. Our PopPK model characterizes the PK profile of edoxaban in Chinese NVAF patients, identifies critical covariates influencing drug exposure, and proposes an evidence-based dosing regimen tailored to this population. This trial was registered at www.clinicaltrials.gov as #NCT05320627.
Autor:innen und Institutionen
- Department of Cardiology, Key Laboratory of Pulmonary Vascular Medicine, State Key Laboratory of Cardiovascular Disease, Center for Respiratory and Pulmonary Vascular Diseases, National Clinical Research Center of Cardi…
- NHC Key Laboratory of Clinical Research for Cardiovascular Medications, National Clinical Research Center of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medic…
- Pharmaron Clinical Services Co., Ltd, Chengdu, China.
- Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences, Shenzhen, China.
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- National High-Level Hospital Clinical Research Funding
- Fuwai Hospital Chinese Academy of Medical Sciences
- Beijing Lisheng Cardiovascular Health Foundation
Zitieren
APA
Deng, Y., Dai, S., Zhu, S., Jiang, J., Chai, L., Liu, Z., Qian, X., Chong, L., Hu, S., Gao, Y., Chen, H., Su, S., Hua, L., & Tian, L. (2026). Edoxaban Population Pharmacokinetics in Chinese Patients with Nonvalvular Atrial Fibrillation: Model-Informed Dose Adjustment. Thrombosis and Haemostasis. https://doi.org/10.1055/a-2802-3641
Vancouver
Deng Y, Dai S, Zhu S, Jiang J, Chai L, Liu Z, et al. Edoxaban Population Pharmacokinetics in Chinese Patients with Nonvalvular Atrial Fibrillation: Model-Informed Dose Adjustment. Thrombosis and Haemostasis. 2026. doi:10.1055/a-2802-3641
BibTeX
@article{Deng2026,
author = {Deng, Yuanrui and Dai, Shiyun and Zhu, Shengsong and Jiang, Juanjuan and Chai, Lin and Liu, Zhiqiang and Qian, Xifeng and Chong, Lingtao and Hu, Song and Gao, Yucheng and Chen, Haoqi and Su, Shijia and Hua, Lu and Tian, Lei},
title = {Edoxaban Population Pharmacokinetics in Chinese Patients with Nonvalvular Atrial Fibrillation: Model-Informed Dose Adjustment},
journal = {Thrombosis and Haemostasis},
year = {2026},
doi = {10.1055/a-2802-3641}
}
EUVIMED